文献速递神经肿瘤

CD70:胶质瘤CAR T细胞治疗的新靶点

CD70, a novel target of CAR T-cell therapy for gliomas.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究评估CD70在胶质瘤中的表达及其作为CAR T细胞治疗靶点的潜力。CD70在IDH野生型原发低级别胶质瘤和胶质母细胞瘤的间充质亚型及复发肿瘤中组成性过表达,与不良生存相关,并诱导CD8+ T细胞死亡。人和小鼠CD70特异性CAR T细胞在体外识别原发CD70+胶质母细胞瘤,并在异种移植和同基因模型中介导已建立胶质母细胞瘤的消退,无明显不良效应。

要点

  • CD70在IDH野生型原发低级别胶质瘤和胶质母细胞瘤的间充质亚型及复发肿瘤中组成性过表达。
  • CD70与这些亚组的不良生存相关,可能与其参与趋化因子产生和选择性诱导CD8+ T细胞死亡有关。
  • CD70特异性CAR T细胞在体外识别原发CD70+胶质母细胞瘤,并在异种移植和同基因模型中介导肿瘤消退。

核心结论

  • CD70是一种在胶质母细胞瘤中普遍表达的免疫抑制配体,可作为胶质瘤CAR T细胞治疗的新靶点。

研究设计与样本

  • 评估52种不同器官来源的正常组织以及原发和复发低级别胶质瘤和胶质母细胞瘤中CD70基因和蛋白表达。
  • 分析CD70与患者总生存及T细胞死亡的相关性。
  • 分别测试人和小鼠CD70特异性CAR对原发人胶质母细胞瘤和小鼠胶质瘤细胞系的作用。
  • 在原位异种移植和同基因模型中检测CAR的抗肿瘤疗效。

主要发现

  • CD70在外周和脑正常组织中未检测到,但在IDH野生型原发低级别胶质瘤和胶质母细胞瘤的间充质亚组及复发肿瘤中组成性过表达。
  • CD70与这些亚组的不良生存相关,可能与其直接参与胶质瘤趋化因子产生和选择性诱导CD8+ T细胞死亡有关。
  • 人和小鼠CD70特异性CAR T细胞在体外识别原发CD70+胶质母细胞瘤,并在异种移植和同基因模型中介导已建立胶质母细胞瘤的消退,无明显不良效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer immunotherapy represents a promising treatment approach for malignant gliomas but is hampered by the limited number of ubiquitously expressed tumor antigens and the profoundly immunosuppressive tumor microenvironment. We identified cluster of differentiation (CD)70 as a novel immunosuppressive ligand and glioma target. METHODS: Normal tissues derived from 52 different organs and primary and recurrent low-grade gliomas (LGGs) and glioblastomas (GBMs) were thoroughly evaluated for CD70 gene and protein expression. The association between CD70 and patients' overall survival and its impact on T-cell death was also evaluated. Human and mouse CD70-specific chimeric antigen receptors (CARs) were tested respectively against human primary GBMs and murine glioma lines. The antitumor efficacies of these CARs were also examined in orthotopic xenograft and syngeneic models. RESULTS: CD70 was not detected in peripheral and brain normal tissues but was constitutively overexpressed by isocitrate dehydrogenase (IDH) wild-type primary LGGs and GBMs in the mesenchymal subgroup and recurrent tumors. CD70 was also associated with poor survival in these subgroups, which may link to its direct involvement in glioma chemokine productions and selective induction of CD8+ T-cell death. To explore the potential for therapeutic targeting of this newly identified immunosuppressive axis in GBM tumors, we demonstrate that both human and mouse CD70-specific CAR T cells recognize primary CD70+ GBM tumors in vitro and mediate the regression of established GBM in xenograft and syngeneic models without illicit effect. CONCLUSION: These studies identify a previously uncharacterized and ubiquitously expressed immunosuppressive ligand CD70 in GBMs that also holds potential for serving as a novel CAR target for cancer immunotherapy in gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018. PMID: 28651374. doi:10.1093/neuonc/nox116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。